Nondaily contraceptive options user benefits, potential for high continuation, and counseling issues

Obstetrical and Gynecological Survey

Volumn 63, Issue 10, 2008, Pages 661-668

  Kottke, Melissa ^a   Cwiak, Carrie ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL;

ANESTHESIA; CONTRACEPTION; COUNSELING; FAMILY PLANNING; FAMILY SIZE; HORMONAL CONTRACEPTION; HUMAN; IMPLANT; INSTRUMENT STERILIZATION; INTRAUTERINE CONTRACEPTIVE DEVICE; REVIEW; RISK ASSESSMENT; SEDATION; SURGICAL RISK; TRANSDERMAL PATCH; UTERINE TUBE LIGATION; VAGINA RING; VASECTOMY; FEMALE; METHODOLOGY; PREGNANCY; STERILIZATION REVERSAL; UNPLANNED PREGNANCY; UNWANTED PREGNANCY;

CONTRACEPTION; FAMILY PLANNING SERVICES; FEMALE; HUMANS; PREGNANCY; PREGNANCY, UNPLANNED; PREGNANCY, UNWANTED; STERILIZATION REVERSAL;

EID: 59649096620     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e318181a7d9     Document Type: Review

References (47)

1. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29.
2. Brown SS, Eisenberg L From the Institute of Medicine: unintended pregnancy and the well-being of children and families. JAMA 1995;274:1332.
3. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. Int J Gynaecol Obstet 2005;89(suppl 1):25S-33S.
4. Zite N, Wuellner S, Gilliam M. Past contraceptive use among women desiring postpartum sterilization. Obstet Gynecol 2005;105(suppl):56S-57S.
5. Cwiak C, Gellasch T, Zieman M. Peripartum contraceptive attitudes and practices. Contraception 2004;70:383-386.
6. Hatcher RA, Trussell J, Stewart F, et al, eds. Contraceptive Technology. 18th ed. New York: Ardent Media, 2004.
7. Rosenberg M, Wugh M, Burnhill M. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92.
8. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77(suppl2):S13-S18.
9. Zacur HA, Hedon B, Mansour D, et al. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion In varied climates and conditions. Fertil Steril 2002;77(suppl 2):32-35.
10. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA 2001;285:2347-2354.
11. van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-174.
12. Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 109(2, Part 1):339-346.
13. Jick S, Kaye JA, Li L, et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestlmate and 35 microg of ethinyl estradiol. Contraception 2007;76:4-7.
14. Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril 2002;77(suppl 2): S19-S26.
15. Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tolerability, and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Hum Reprod 2001;16: 469-475.
16. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865-870.
17. Bjarnadottlr RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-395.
18. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996;41(suppl): 381-390.
19. Mishell DR Jr, Kletzky OA, Brenner PF, et al. The effect of contraceptive steroids on hypothalamic-pltultary function. Am J Obstet Gynecol 1977;128:60-74.
20. Hatcher RA, Zieman M, Cwlak C, et al, eds. A Pocket Guide to Managing Contraception. Tiger, Georgia: Bridging the Gap Foundation, 2005.
21. Kaunitz AM. Injectable contraception: new and existing options. Obstet Gynecol Clin North Am 2000;27:741-780.
22. Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 1974;10:181-202.
23. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006;73:470-487.
24. Implanon (etonogestrel Implant) Prescribing information. Organon USA, Roseland, NJ; July 2006.
25. Makaralnen L, van Beek A, Tuomlvaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998;69:714-721.
26. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319-326.
27. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
28. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova T. Contraception 1992;46:575-584.
29. Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-567.
30. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 meg/day and the Copper T380Ag intrauterine contraceptive devices: a multicenter study. Fertil Steril 1994;61:70-77.
31. Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-788.
32. Mirena [product monograph]. Montville, NJ: Berlex Laboratories; 2003.
33. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No 337: noncontraceptive uses of the levonorgestrel Intrauterine system. Obstet Gynecol 2006;107:1479-1482.
34. World Health Organization. Long-term reversible contraception: 12 years of experience with the TCu380A and TCu220C. Contraception 1997;56:341-352.
35. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120-128.
36. Schmidt JE, Hillis SD, Marchbanks PA, et al. Requesting information about and obtaining reversal after tubal sterilization: findings from the US Collaborative Review of Sterilization. Fertil Steril 2000;74:892-898.
37. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-1170.
38. Jamleson DJ, Hillis SD, Duerr A, et al. Complications of interval laparoscopic tubal sterilization: findings from the US Collaborative Review of Sterilization. Obstet Gynecol 2000;96: 997-1002.
39. Escobedo LG, Peterson HB, Grubb GS, et al. Case-fatality rates for tubal sterilization in US hospitals, 1979 to 1980. Am J Obstet Gynecol 1989;160:147-150.
40. Peterson HB, Jeng G, Folger SG, et al. The risk of menstrual abnormalities after tubal sterilization: findings from the US Collaborative Review of Sterilization. N Engl J Med 2000;343: 1724-1726.
41. Johnson LK, Edelman A, Jensen J. Patient satisfaction and the Impact of written material about postpartum contraceptive decisions. Am J Obstet Gynecol 2003;155:1202-1204.
42. World Health Organization. Selected Practice Recommendations for Contraceptive Use. 2nd ed. Geneva: World Health Organization; 2005.
43. Mulders TM, Dieben TO, Coelingh Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594-2599.
44. Allyn DP, Leton DA, Westcott NA, et al. Presterilization counseling and women's regret about having been sterilized. J Reprod Med 1986;31:1027-1032.
45. Leader A, Galan N, George R, et al. A comparison of definable traits In women requesting reversal of sterilization and women satisfied with sterilization. Am J Obstet Gynecol 1983;145: 198-202.
46. Hardy E, Bahamondes L, Osis MJ, et al. Risk factors for tubal sterilization regret, detectable before surgery. Contraception 1996;54:159-162.
47. Kelekci S, Erdemoglu E, Kutluk S, et al. Risk factors for tubal ligation: regret and psychological effectsimpact of Beck Depression Inventory. Contraception 2005;71:417-420.